Calidi Biotherapeutics, Inc.
New York Stock Exchange AmericanRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is a clinical-stage biotechnology company developing oncolytic virotherapies for cancer treatment. The company engineers viruses to selectively target and destroy tumor cells while stimulating the patient's immune response; its lead product candidate, CNCT-101 (also known as SuperNova), is an enhanced herpes simplex virus 1 (HSV-1) expressing human interleukin-12 (IL-12) under a tumor-selective promoter, currently in Phase 1 clinical trials for glioblastoma and solid tumors. Additional pipeline programs include CNCT-202, a stem cell-delivered HSV-1 therapy; intravenous HSV platforms; and preclinical assets like RNA-based therapies and nanoparticle-delivered HSV, all leveraging the company's Switchable ImmunoViroTherapy (SIVTherapy) platform that combines oncolytic viruses with stem cell delivery for systemic tumor targeting. Calidi operates in the oncology segment of the biopharmaceutical industry, targeting patients with high-grade gliomas, metastatic solid tumors, and other difficult-to-treat cancers; its therapies aim at academic medical centers, hospitals, and oncology clinics globally. Founded in 2019 and headquartered in San Diego, California, the company has no listed subsidiaries or parent relationships. In recent developments, Calidi completed a reverse merger with Shiftpixy, Inc. in August 2024, enabling its public listing on the NYSE American under the CLDI ticker and providing growth capital. The company dosed the first patient in its pivotal SuperNova (CNCT-101) trial for glioblastoma in late 2024, marking a key advancement toward potential FDA accelerated approval; it also expanded the trial to include liver and other solid tumors. Calidi announced positive preclinical data for its intravenous oncolytic virus programs and stem cell-delivered platforms in 2025, alongside partnerships with institutions like City of Hope for clinical collaborations; no major funding rounds or acquisitions were reported in the last 1-2 years, though it maintains ongoing capital raises to support pipeline progression.
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
Calidi Biotherapeutics Provides Required NYSE American Disclosure
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
Calidi Biotherapeutics (CLDI) Stock Plunges 35% After Hours — Here's Why
Calidi Biotherapeutics Announces Proposed Public Offering